Wu, AnnGay, CharleneRett, Melisa D.Stout, NatashaWeiss, ScottFuhlbrigge, Anne2016-05-172015Wu, Ann Chen, Charlene Gay, Melisa D Rett, Natasha Stout, Scott T Weiss, and Anne L Fuhlbrigge. 2015. “Pharmacogenomic Test That Predicts Response to Inhaled Corticosteroids in Adults with Asthma Likely to Be Cost-Saving.” Pharmacogenomics 16 (6) (April): 591–600. doi:10.2217/pgs.15.28.1462-2416http://nrs.harvard.edu/urn-3:HUL.InstRepos:27015682Aim: To identify the clinical and economic circumstances under which a pharmacogenomic test that predicts response to inhaled corticosteroids might be a cost-effective option for individuals with asthma. Materials & methods: We synthesized published data on clinical and economic outcomes to project 10-year costs, quality-adjusted life-years and cost–effectiveness of pharmacogenomic testing for inhaled corticosteroid response. We assumed the pharmacogenomic test cost was $500 with a sensitivity and specificity of 84 and 98%, respectively. These were varied in sensitivity analyses. Results: Both strategies, pharmacogenomic testing for inhaled corticosteroid response and no testing conferred 7.1 quality-adjusted life-years. Compared with no testing, pharmacogenomic testing costs less. Conclusion: Pharmacogenomic testing for asthma is cost-saving and noninferior in improving health.en-USasthmacost–effectivenessinhaled corticosteroidspharmacogenomicspredictive testJournal Article2016-05-1710.2217/pgs.15.28